Natera, Inc. (NASDAQ:NTRA) Stock Position Reduced by Brown Advisory Inc.

Brown Advisory Inc. cut its stake in shares of Natera, Inc. (NASDAQ:NTRA) by 3.1% during the first quarter, according to its most recent disclosure with the SEC. The institutional investor owned 4,680 shares of the medical research company’s stock after selling 148 shares during the period. Brown Advisory Inc.’s holdings in Natera were worth $662,000 at the end of the most recent reporting period.

Other institutional investors have also recently added to or reduced their stakes in the company. LRI Investments LLC acquired a new stake in Natera in the fourth quarter valued at approximately $29,000. Rakuten Securities Inc. lifted its stake in Natera by 117.8% in the first quarter. Rakuten Securities Inc. now owns 220 shares of the medical research company’s stock valued at $31,000 after acquiring an additional 119 shares during the last quarter. ORG Partners LLC acquired a new stake in Natera in the first quarter valued at approximately $32,000. EverSource Wealth Advisors LLC lifted its stake in Natera by 372.9% in the fourth quarter. EverSource Wealth Advisors LLC now owns 331 shares of the medical research company’s stock valued at $52,000 after acquiring an additional 261 shares during the last quarter. Finally, Steward Partners Investment Advisory LLC lifted its stake in Natera by 1,328.0% in the fourth quarter. Steward Partners Investment Advisory LLC now owns 357 shares of the medical research company’s stock valued at $57,000 after acquiring an additional 332 shares during the last quarter. 99.90% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of research firms have issued reports on NTRA. Wall Street Zen cut shares of Natera from a “hold” rating to a “sell” rating in a research note on Saturday, May 17th. Piper Sandler lifted their target price on shares of Natera from $205.00 to $210.00 and gave the company an “overweight” rating in a research note on Thursday, May 15th. Barclays boosted their price objective on shares of Natera from $160.00 to $190.00 and gave the stock an “overweight” rating in a research note on Friday, May 9th. Finally, UBS Group boosted their price objective on shares of Natera from $211.00 to $218.00 and gave the stock a “buy” rating in a research note on Friday, May 9th. One research analyst has rated the stock with a sell rating and fifteen have issued a buy rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $184.63.

Natera Price Performance

NASDAQ:NTRA opened at $158.18 on Tuesday. The stock has a market cap of $21.60 billion, a P/E ratio of -107.60 and a beta of 1.73. Natera, Inc. has a one year low of $92.14 and a one year high of $183.00. The company has a fifty day moving average price of $161.05 and a 200 day moving average price of $158.41.

Natera (NASDAQ:NTRA) last released its earnings results on Thursday, May 8th. The medical research company reported ($0.50) EPS for the quarter, beating the consensus estimate of ($0.59) by $0.09. The firm had revenue of $501.83 million during the quarter, compared to analysts’ expectations of $446.68 million. Natera had a negative net margin of 10.36% and a negative return on equity of 18.29%. The business’s quarterly revenue was up 36.5% compared to the same quarter last year. During the same period in the prior year, the company earned ($0.56) EPS. As a group, equities research analysts anticipate that Natera, Inc. will post -1.49 EPS for the current year.

Insider Buying and Selling at Natera

In other Natera news, insider Solomon Moshkevich sold 3,000 shares of the business’s stock in a transaction on Tuesday, July 1st. The shares were sold at an average price of $166.77, for a total value of $500,310.00. Following the sale, the insider owned 130,205 shares of the company’s stock, valued at $21,714,287.85. The trade was a 2.25% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, CFO Michael Burkes Brophy sold 2,018 shares of the business’s stock in a transaction on Monday, April 28th. The shares were sold at an average price of $152.18, for a total transaction of $307,099.24. Following the completion of the sale, the chief financial officer directly owned 73,539 shares in the company, valued at $11,191,165.02. This trade represents a 2.67% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 53,272 shares of company stock worth $8,345,368. Corporate insiders own 7.60% of the company’s stock.

Natera Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.